COPD Treatment Market Players:
- GlaxoSmithKline plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Merck & Co., Inc.
- Sunovion Pharmaceuticals Inc.
- Chiesi Farmaceutici S.p.A.
- Circassia Pharmaceuticals plc
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of COPD treatment is evaluated at USD 23.01 billion.
The global COPD treatment market size exceeded USD 21.92 billion in 2025 and is set to expand at a CAGR of more than 5.5%, surpassing USD 37.44 billion revenue by 2035.
Asia Pacific chronic obstructive pulmonary disease (COPD) treatment market is expected to capture 39% share by 2035, fueled by rising prevalence of COPD and government initiatives.
Key players in the market include GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V.
